I am familiar with the Hughes-trial, however you also have other trials like the Austrian-study or NSABP B21 pointing to a higher recurrence free benefit through RT.
The point that RT does not lead to increased overall survival is valid, but the same could also be said for tamoxifen in this very-low-risk patient population.
Yet no physician would probably defer from giving tamoxifen, right?
In the end, you need to weight the pros and cons for RT. We know that the RT of the breast leads to very low toxicity nowadays, perhaps even lower than tamoxifen in some cases (?).
RT is certainly more effective than tamoxifen, when it comes to local control as NSABP B21 demonstrated.
Furthermore hypofractionation is quite convenient for many patients, so that you can treat patients like her in 3 weeks with substantially reduced costs.
And certainly the whole partial breast options are out there (although we don't actually know, if we can do that in (i+)-patients), but if the patient had gotten an Intrabeam-treatment noone probably would be discussing tangents, right?